GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Net Change in Cash

Fate Therapeutics (Fate Therapeutics) Net Change in Cash

: $-19.51 Mil (TTM As of Dec. 2023)
View and export this data going back to 2013. Start your Free Trial

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Fate Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was $8.54 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-19.51 Mil.

Fate Therapeutics Net Change in Cash Historical Data

The historical data trend for Fate Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fate Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -90.70 82.53 -33.76 -72.25 -19.51

Fate Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.76 -19.31 4.73 -13.47 8.54

Fate Therapeutics Net Change in Cash Calculation

Fate Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-132.263+112.665+0.085+0
=-19.51

Fate Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-36.637+45.353+-0.18+0
=8.54

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fate Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Fate Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Fate Therapeutics (Fate Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fate Therapeutics Inc (NAS:FATE) » Definitions » Net Change in Cash
Comparable Companies
ATXS ALVR IMRX CRMD RLYB QSI MACK OBIO PSTX IKNA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
F6T:Germany F6T:Germany
Address
12278 Scripps Summit Drive, San Diego, CA, USA, 92131
Website
https://www.fatetherapeutics.com
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and immune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Executives
J Scott Wolchko director, officer: President and CEO C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Dulac Edward J Iii officer: Chief Financial Officer FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Bahram Valamehr officer: Chief Development Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Cindy Tahl officer: See Remarks C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, STE 200, SAN DIEGO CA 92121
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Yuan Xu director C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Brian T. Powl officer: Chief Commercial Officer C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO CA 92131
Yu-waye Chu officer: See Remarks FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
John Mendlein director
Mark Plavsic officer: Chief Technical Officer C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Karin Jooss director C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Timothy P Coughlin director 339 NORTH GRANADOS AVE, SOLANA BEACH CA 92075
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Robert S Epstein director

Fate Therapeutics (Fate Therapeutics) Headlines

From GuruFocus

FATE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Fate Therapeutics, Inc. and Encourages Investors to Contact the Firm

By Business Wire Business Wire • 03-22-2023

SHAREHOLDER ALERT: Morris Kandinov Investigating FATE, HAFC, PEGA, and CVNA; Shareholders are Encouraged to Contact the Firm

By Marketwired • 08-21-2023

Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results

By sperokesalga sperokesalga • 04-24-2023

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important March 22 Deadline in Securities Class Action - FATE

By PRNewswire PRNewswire • 03-18-2023

Fate Therapeutics Inc (FATE) Reports Q3 2023 Financial Results and Business Updates

By GuruFocus Research • 11-08-2023

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm

By sperokesalga sperokesalga • 03-18-2023

FATE THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

By Business Wire • 06-22-2023

Fate ALERT: Bragar Eagel & Squire, P.C. is Investigating Fate Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

By Business Wire Business Wire • 06-09-2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Fate Therapeutics, Inc. (FATE)

By Business Wire Business Wire • 03-21-2023

FATE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of March 22, 2023 in the Class Action Filed on Behalf of Fate Therapeutics, Inc. Shareholders

By PRNewswire PRNewswire • 03-21-2023